TABLE 8

Summary of XtremeCT values (mean ± S.D.) as percentage change from acclimation period (n = 4) after weekly subcutaneous administration of TransCon CNP or daily CNP-39 molecule for 26 wk

TreatmentControlDaily CNP-39 MoleculeTransCon CNP
CNP DoseVehicle20 µg/kg Per Day40 µg/kg Per Week100 µg/kg Per Week
Right Radius, Distal Metaphysis—Trabecular Region
Trabecular region vBMDmg HA/cm319.8 ± 10.318.2 ± 14.927.0 ± 17.916.5 ± 10.7
Trabecular tissue BMDmg HA/cm3−0.27 ± 2.10.45 ± 1.8−0.12 ± 1.11.7 ± 0.83
Trabecular BV/TV%18.2 ± 8.218.7 ± 15.029.9 ± 19.218.2 ± 12.4
Trabecular number1/mm13.2 ± 11.65.8 ± 6.012.9 ± 8.88.9 ± 5.3
Trabecular thicknessmm4.6 ± 3.78.9 ± 6.716.2 ± 14.514.0 ± 11.8
Trabecular separationmm−14.6 ± 8.4−5.9 ± 7.0−12.0 ± 9.0−10.5 ± 5.0
Right Radius, Distal Metaphysis—Cortical Region
Cortical region vBMDmg HA/cm3−5.2 ± 1.2−7.0 ± 2.2−8.7 ± 2.9−2.7 ± 2.3
Cortical tissue BMDmg HA/cm3−3.8 ± 1.4−5.9 ± 1.6−5.9 ± 1.2−2.4 ± 1.8
Cortical thicknessmm−3.6 ± 16.0−9.4 ± 11.2−16.7 ± 11.54.5 ± 10.7
Right Radius, Distal Diaphysis—Cortical Region
Cortical region vBMDmg HA/cm3−1.8 ± 1.6−3.3 ± 1.6−7.8 ± 9.8−2.4 ± 2.3
Cortical tissue BMDmg HA/cm3−4.8 ± 1.9−6.7 ± 1.4−6.3 ± 3.6−3.7 ± 1.6
Cortical thicknessMm7.0 ± 3.08.2 ± 5.01.1 ± 8.48.9 ± 4.7
  • BMD, bone mineral density; BV, bone volume; TV, tissue volume.